LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) aims to deliver $80 billion
in total revenue by 2030, up from $45.8 billion in 2023. The target will be
achieved through significant growth in its existing oncology, biopharmaceuticals
and rare disease portfolio, and by launching an expected 20 new medicines before
the end of the decade, the British drug major said in a statement on Tuesday.

The company said, to drive sustained growth beyond 2030, it will continue
investing in transformative new technologies and platforms that will shape the
future of medicine.

The company plans to launch 20 new medicines by 2030, many with the potential to
generate more than $5 billion in peak year revenues.

AstraZeneca noted that it will maintain its strategic commitment to research and
development while emphasizing productivity company-wide, aiming to leverage
operations and achieve its ambition of a mid-30s percentage Core operating
margin by 2026. Beyond 2026, the Core operating margin will be influenced by
portfolio evolution, with the company targeting at least the mid-30s percentage
range.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX